Health Care · Biological Products, (No Diagnostic Substances) · NYSE · CIK 946644 · no price history on file
Price
Price series unavailable — No prices available for AIM in [1900-01-01, 2026-07-30]. This symbol may require bring-your-own-key (BYOK) data.
At a glance
Short interest is FINRA semi-monthly, settlement 2026-07-15.
Key fundamentals
AIM is not in the screener universe.
Trailing returns
No return windows available for AIM.
Risk
No risk analytics available for AIM.
Top institutional holders13F 2026-Q1
| Manager | Shares | Value | % sh out | QoQ |
|---|
| Virtu Financial LLC | 50,895 | $30,000 | — | new |
| GEODE CAPITAL MANAGEMENT, LLC | 29,918 | $17,501 | — | +72.2% |
| HRT FINANCIAL LP | 26,032 | $15,000 | — | new |
| XTX Topco Ltd | 20,590 | $12,045 | — | new |
| JANE STREET GROUP, LLC | 20,047 | $11,727 | — | new |
| VANGUARD FIDUCIARY TRUST CO | 17,519 | $10,249 | — | new |
| Tower Research Capital LLC (TRC) | 4,668 | $2,731 | — | +3634.4% |
| MORGAN STANLEY | 864 | $505 | — | +0.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
Latest reported quarters
No reported quarters on file for AIM.
Basis & disclosures
- End-of-day only. Every price on this sheet is a stored CLOSE. Nothing here is live, intraday or delayed-real-time, and the sheet does not update after it is printed.
- Nothing is imputed. A figure that is not in the underlying filing or feed renders as “—”. We never fill a gap with an estimate, a peer median or a carried-forward value.
- Mixed as-of dates by design. Prices are at the last close; fundamentals are at the latest reported fiscal period; 13F ownership is at the latest filed quarter (45+ days in arrears); short interest is the latest FINRA settlement. Each block states its own basis above.
- Not investment advice. Model fair values, reverse-DCF grades and confidence labels are the output of published, disclosed methods on public filings — they are analysis, not a recommendation, a price target or a solicitation.
- Fundamentals and ownership derive from SEC EDGAR (and equivalent foreign registers); prices from a licensed end-of-day vendor, shown under a neutral source label. Full methodology at spzco.com/methodology.
